INVESTIGADORES
CHULUYAN Hector Eduardo
congresos y reuniones científicas
Título:
SECRETORY LEUKOPROTEASE INHIBITOR IMPROVES SURVIVAL OF SKIN ALLOGRAFTS
Autor/es:
GUERRIERI D; ROMEO HE; INCARDONA C; CHULUYAN E
Lugar:
Vancouver, Canada
Reunión:
Congreso; The XXIII International Congress of the Transplantation Society; 2010
Institución organizadora:
Transplantation Society
Resumen:
Introduction: Secretory leukoprotease inhibitor (SLPI) is an 11.7 kDa cationic non-glycosylated serine protease inhibitor with wound healing and NF-kappaB inhibitory activity. Previously, we observed that SLPI decreases the lymphocyte proliferation and IFNγ production but increases IL-10 and IL-4. The aim of this work was to analyze whether SLPI can reduce acute graft rejection and delayed type hypersensitivity (DTH). Methods: a C57BL/6 (B6) (H-2Kb) to BALB/c (H-2Kd) mice skin transplantation model was used. SLPI was given s.c. three days before the implant and every day along the experiment. Another group of mice was treated with tacrolimus (i.p.) instead of SLPI or SLPI (s.c.) plus tacrolimus (i.p.). Rejection was defined as 80% loss of viable epidermal graft tissue. DTH’s activity was evaluated in two models: i) C57BL/6 mice cells was given to sensitize BALB/c mice, and ii) Dinitrochlorobenzene (DNCB). Results: at day 8, the rejection of skin allograft was observed for 60 % of non-treated mice and 20 % for SLPI treated mice, while no rejection was observed for tacrolimus treated mice. At day 9, rejection of 82 %, 79 %, 20 and 25 % was observed for control, SLPI, tacrolimus and tacrolimus+SLPI treated mice, respectively. At day 11, the 90 % of the animals that received tacrolimus rejected the graft vs 50 % of the animals that received tacrolimus+SLPI. In the latter group, 100 % of the animals rejected the graft by day 13th. Furthermore, the administration of allogeneic cells or DNCB induced an edema in the ear of sensitized animals. Nevertheless, the edema was not observed when the animals were pre-treated with SLPI (p <0.05). CONCLUSION: SLPI alone or with tacrolimus improves survival of the skin allograft implants and diminishes the inflammatory response in two models of DTH. These results suggest that the SLPI is an immunomodulator that might be a new therapeutic tool in organ transplants.